Cell Therapy News/Articles, page-17358

Thanks Bedger, it's always good to know what else is out there.

While the the FDA has granted Fast Track designation to this therapy, it's not a given that they will get to market before MSB as, by their own admission, "Independent clinical investigation is needed for validation."

Even if they do get to market before MSB, their product is autologous vs allogeneic, with all the disadvantages that come with that - increased time to apply therapy, increased expense, increased risk and patient discomfort and inconvenience. If MSB's product gets to market, all else being equal, I can't see each patient choosing to undergo a bone marrow cell extraction procedure, over an off the shelf cell product like MSB's.

While there are other competitors in this space, this therapy is not one that concerns me. Having said that, I'd be a lot of more comfortable if I knew that MSB was moving at speed with bringing their products to market.